Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -61.34% | 14.85% | 130.40% | -2.59% | 96.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.34% | 14.85% | 130.40% | -2.59% | 96.38% |
| Cost of Revenue | 51.80% | 34.41% | 132.15% | 2.09% | 8.00% |
| Gross Profit | -875.00% | 52.43% | -139.21% | -28.95% | 74.73% |
| SG&A Expenses | 14.43% | 4.67% | 10.25% | -4.97% | 4.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.68% | 16.37% | 64.90% | -2.00% | 5.91% |
| Operating Income | -80.63% | -16.73% | -28.14% | 1.41% | 15.80% |
| Income Before Tax | 105.08% | -15.59% | -35.02% | -891.40% | -425.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 105.08% | -15.59% | 127.45% | -891.40% | -425.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 38.00% | -675.00% | -78.26% | 12.12% | -869.23% |
| Net Income | 104.86% | -16.26% | 126.00% | -881.58% | -428.89% |
| EBIT | -80.63% | -16.73% | -28.14% | 1.41% | 15.80% |
| EBITDA | -83.18% | -16.78% | -28.29% | 2.46% | 16.70% |
| EPS Basic | 104.42% | -7.10% | 126.47% | -708.07% | -337.38% |
| Normalized Basic EPS | 108.39% | -8.77% | -36.05% | -705.94% | -125.79% |
| EPS Diluted | 77.21% | -50.00% | 126.47% | -708.07% | -337.38% |
| Normalized Diluted EPS | 108.16% | -1.75% | -36.05% | -705.94% | -125.79% |
| Average Basic Shares Outstanding | 9.26% | 8.39% | -1.26% | 21.19% | 20.94% |
| Average Diluted Shares Outstanding | 14.50% | 15.54% | -1.26% | 21.19% | 20.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |